(1 - 9 von 10
)
7518.T - Net One Systems Co., Ltd. | Stock Price & Latest News |...
www.reuters.com
Connect to the most current information on stocks and bonds on Reuters.com. Finance and investing news on NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com.
onkoserv - der aktuellste und unabhängige deutsche Informationsdienst...
www.onkoserv.de
Onkoserv ist der aktuellste deutsche Informationsdienst für die klinische Onkologie
Brocade and Net One Systems Extend Strategic Business Alliance
www.finanznachrichten.de
... networking markets in Japan present tremendous growth potential for us and our partners," said Takayuki Yoshino, President and CEO of Net ...
Darmkrebs: TAS-102 erreicht primären Endpunkt bei der Verbesserung...
www.krebs-nachrichten.de
Weitere detaillierte Ergebnisse aus der globalen Phase-III-RECOURSE-Studie werden am 28. Juni bei einem Vortrag beim 16. ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spanien vorgetragen (Vortragender: Dr. Takayuki Yoshino vom National Cancer Center Hospital East, Japan). Informationen zu RECOURSE
Drug trial offers hope to patients with advan | EurekAlert!
www.eurekalert.org
A new drug treatment could offer hope to patients with advanced colorectal cancer who were intolerant of or did not respond to standard treatments, according...
New drug combination extends survival of patients with metastatic...
www.dana-farber.org
Research led by scientists at Dana-Farber showed a new drug combination lengthened the lives of patients with metastatic colorectal cancer.
TAS-102, bevacizumab promising for refractory colorectal cancer
www.healio.com
... have increased the survival time of patients with metastatic colorectal cancer compared with standard-of-care treatment,” Takayuki Yoshino, ...
The ASCO Post
ascopost.com
... therapies,” said Takayuki Yoshino, MD, of the National Cancer Centre Hospital East in Chiba, Japan, lead author of the phase III RECOURSE ...
Phase III Trial Shows Improved Survival with TAS-102 in Metastatic...
www.esmo.org
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory
sortiert nach Relevanz / Datum